Stocks
Telix Pharmaceuticals LimitedTLX
NASDAQHealthcareBiotechnology$11.74
Price as of · delayed, not real-time
A radiopharmaceutical company focused on developing and commercializing targeted molecularly targeted radiation therapies and diagnostic imaging agents, primarily for oncology. Its lead product, Illuccix, is approved for prostate cancer imaging, and the company is advancing a pipeline of therapeutic candidates. Investors track TLX for its commercial growth in precision medicine and its expanding global footprint in nuclear medicine.
52W Range: $6.28-$12.48
Congressional Interest in Telix Pharmaceuticals Limited (TLX)
No congressional trades have been disclosed for Telix Pharmaceuticals Limited (TLX) yet. All data is sourced from STOCK Act periodic transaction reports filed with Congress.
Total Disclosures
0
Unique Politicians
0
Buys
0
Sells
0
Who in Congress Is Trading TLX?
No congressional trades found for this stock.